Durvalumab and Stereotactic Body Radiotherapy Combination Potentially Beneficial Against NSCLC
In a recent article in The Lancet Oncology, researchers from New York-Presbyterian and Weill Cornell Medical Center in New York City conducted a randomized, controlled phase II trial to determine the effects of using stereotactic body radiotherapy in patients with early-stage non–small cell lung cancer
(NSCLC) who were also prescribed the anti-PD-L1 (programmed death-ligand 1) antibody, durvalumab. Read more.

First Targeted Therapy Approved for Adults With KRAS G12 C–Mutated NSCLC
The FDA announced the accelerated approval of Lumakras (sotorasib) as the first treatment for adults with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer (NSCLC), determined by an FDA-approved test, who have received at least one prior systemic therapy. Lumakras
received accelerated approval based onoverall response rate and duration of response. Read more.

Promising Study Results for Pralsetinib in Patients With RET Fusion–Positive NSCLC
In a recent clinical trial reported in The Lancet Oncology, researchers conducted the ARROW trial—a multicohort, open-label, phase I/II study performed at 71 sites. The study supported the September 2020 FDA accelerated approval of the oral rearranged during transfection (RET) inhibitor pralsetinib for the treatment of adult patients with metastatic RET fusion–positive non–small cell lung cancer (NSCLC). Read more.